...
首页> 外文期刊>Medicine. >Clinical analysis of lectin-like oxidized low-density lipoprotein receptor-1 in patients with in-stent restenosis after percutaneous coronary intervention
【24h】

Clinical analysis of lectin-like oxidized low-density lipoprotein receptor-1 in patients with in-stent restenosis after percutaneous coronary intervention

机译:依牙冠状动脉介入后支架再狭窄患者凝集素样氧化低密度脂蛋白受体-1的临床分析

获取原文

摘要

In-stent restenosis (ISR) is the most common complication associated with percutaneous coronary intervention (PCI). Although some studies have reported an association between lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) and ISR, not enough clinical validation data are available to support this link. Here, we report our cross-sectional study aimed at exploring the feasibility of LOX-1 as a biomarker for the prognostic diagnosis of patients undergoing PCI. Three groups were included: ISR group, including 99 patients with ISR diagnosed with coronary arteriography (CAG) after PCI; lesion group, comprising 87 patients with coronary artery stenosis (<50%) diagnosed with CAG after PCI; and control group, consisting of 96 volunteers with no coronary artery disease. The levels of LOX-1 were measured in each patient by using an enzyme-linked immunosorbent assay, and their general information as well as laboratory parameters were recorded and followed up during a period of 2 years. LOX-1 levels gradually increased after PCI along with the progression of the lesion in the 3 groups. The levels of LOX-1 were significantly higher in the ISR group than in the other 2 groups ( P < .001). LOX-1 levels were correlated with the levels of uric acid (UA) (r = 0.289, P = .007), creatinine (CREA) (r = .316, P = .003), and high-density lipoprotein cholesterol (HDL-C) (r = ?0.271, P = .012), whereas no statistically significant correlation was detected with the Gensini score (r = 0.157, P = .141). The sensitivity and specificity of LOX-1 were 81.5% and 55.7%, respectively, with the most optimal threshold (5.04 μg/L). The area under curve (AUC) of the receiver operator characteristic (ROC) curve of LOX-1 was 0.720, and LOX-1 had the highest AUC compared with CREA, UA, and HDL-C, both individually and in combination. A high level of LOX-1 in the early period after PCI has a certain predictive power and diagnostic value for ISR. However, the level of LOX-1 is not related to the Gensini score of coronary artery after PCI, and CREA and UA, which are weakly related to LOX-1, have no obvious synergy in the diagnosis of ISR with LOX-1.
机译:支架再狭窄(ISR)是与经皮冠状动脉干预(PCI)相关的最常见的并发症。虽然一些研究报告了凝集素氧化低密度脂蛋白受体-1(LOX-1)和ISR之间的关联,但没有足够的临床验证数据来支持这种联系。在这里,我们报告了我们的横截面研究,旨在探讨LOX-1作为生物标志物的可行性,以进行接受PCI的患者的预后诊断。包括三组:ISR组,包括99例ISR诊断患有冠状动脉造影(CAG)的ISR;病变组,包含87例冠状动脉狭窄患者(<50%)被诊断为CPI后患有CAG;和对照组,由96名志愿者组成,没有冠状动脉疾病。通过使用酶联免疫吸附试验在每位患者中测量LOX-1的水平,并记录它们的一般信息以及实验室参数,并在2年期间进行。 PCI后LOX-1水平随后逐渐增加,随着3组病变的进展。 ISR组中LOX-1的水平显着高于其他2组(P <.001)。 LOX-1水平与尿酸(UA)的水平相关(R = 0.289,P = .007),肌酐(CREA)(R = .316,P = .003)和高密度脂蛋白胆固醇(HDL -C)(r = 0.271,p = .012),而使用Gensini得分未检测到统计学上显着的相关性(r = 0.157,p = .141)。 LOX-1的敏感性和特异性分别为81.5%和55.7%,最佳阈值(5.04μg/ L)。 LOX-1的接收器操作员特征(ROC)曲线的曲线(AUC)下的区域为0.720,并且LOX-1与CREA,UA和HDL-C相比具有最高的AUC,无论是单独还是组合。 PCI初期的高水平LOX-1对ISR具有一定的预测力和诊断价值。然而,LOX-1的水平与PCI之后的冠状动脉的Ge​​nsini得分与冠状动脉的Ge​​nsini得分无关,并且Crea和UA与Lox-1弱相关,在罗克斯-1的ISR诊断中没有明显的协同作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号